We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Diagnostic Products Detect Prostate Cancer

By LabMedica International staff writers
Posted on 19 Jun 2017
A novel sample collection device was designed to support a urine-based non-invasive "liquid biopsy" molecular diagnostic test that determines the risk for developing high-grade prostate cancer.

The biomedical company MDxHealth SA (Herstal, Belgium) has announced the European launch of its CE-marked UrNCollect device for use with the SelectMDx in vitro diagnostic (IVD) PCR test kit for prostate cancer.

UrNCollect is a user-friendly device that enables the hygienic and standardized collection of the first 16 milliliters of the urine stream and reduces laboratory errors by automating preservative mixing without additional handling or pipetting.

The SelectMDx PCR kit enables diagnostic laboratories with manual and automated RNA extraction and PCR platforms to perform the liquid biopsy test in their own facility. More...
Laboratories that are not equipped to use the IVD PCR kit can have samples processed at MDxHealth’s state-of-the-art ISO-certified diagnostic facilities in Nijmegen, the Netherlands or Irvine, California, USA.

“Many of our current customers are eager to start using the IVD PCR kit so they can run the SelectMDx for prostate cancer test in their own labs,” said Dr. Jan Groen, CEO of MDxHealth. “It is well-timed that our UrNCollect device is launching as a complement to the SelectMDx IVD PCR kit because pilot studies demonstrated that patients and physicians found the device easier to use than traditional urine collection tubes.”

A technical validation study that assessed and confirmed the robustness, reproducibility, and interlaboratory performance of SelectMDx was published in the May 11, 2017, issue of the journal Translational Medicine Communications.

Related Links:
MDxHealth


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.